Testing a shorter, stronger radiation schedule for lung cancer
Part of Cancer, Injuries & trauma, Lungs & breathing clinical trials.
This trial studies a different way to deliver radiation to people with locally advanced, non-operable non-small cell lung cancer. It may help by aiming to treat the tumor effectively with a different radiation timing and dose pattern.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have confirmed non-small cell lung cancer that cannot be removed with surgery (locally advanced and inoperable).
- You are 18 years or older and can sign informed consent.
- You are well enough for daily activities (performance status 0 to 2).
- You can attend study visits and follow-up testing as required.
- If you could become pregnant, your pregnancy test must be negative; and you must use effective birth control during treatment and for one month after (for fertile participants).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding a high, focused dose of radiation to the usual first treatment (chemo and/or immunotherapy) can help people with non-small cell lung cancer that has spread to a limited number of spots (up to 5). The goal is to see if this approach improves how well the treatment works.
This study tests a new way of giving radiation for people with locally advanced non-small cell lung cancer (NSCLC), along with a chemotherapy medicine (navelbine). It may help by improving how well the treatment controls the cancer in the chest while watching for side effects.
This trial studies a new way of giving radiation therapy to the chest for lung cancer that is growing quickly. The approach uses a special schedule to damage the cancer more effectively, which might improve how well the treatment works.
This study compares two different radiation schedules for stage III non-small cell lung cancer, both combined with chemotherapy and immunotherapy. It aims to see whether giving radiation in a different way can work as well (or better) and be safe while treating the cancer.
This trial tests a new schedule of chemo-radiation (fewer, stronger sessions) followed by an immunotherapy drug called tislelizumab. The goal is to see if this approach works better than the standard longer schedule for people with stage III lung cancer that can't be surgically removed.
This trial tests combining immunotherapy with a shorter course of chemoradiation for locally advanced non-small cell lung cancer that hasn't spread. It aims to see if this approach is more effective and tolerable than standard treatment.
Hear when a new Radiotherapy Side Effect trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.